China Preclinical Imaging Market (2024-2029)
The China Preclinical Imaging Market was valued at $32.7 Million in 2024 and projected to reach to $41.9 Million by 2029, representing a compound annual growth rate of 5.1%. China's preclinical imaging market is positioned for steady growth as the nation strengthens its position as a global pharmaceutical research hub.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Preclinical Imaging Market Trends and Insights
- China's rapid advancement in pharmaceutical research and development, coupled with increased government investment in life sciences infrastructure, is driving demand for sophisticated preclinical imaging technologies.
- The market in China benefits from a growing number of contract research organizations (CROs) and academic institutions expanding their research capabilities. The preclinical imaging sector in China is characterized by rising adoption of advanced modalities such as micro-CT, micro-MRI, and optical imaging systems.
- China's emphasis on drug discovery innovation and regulatory modernization is accelerating the integration of preclinical imaging into research workflows.
- Between 2024 and 2029, China is expected to see increased capital expenditure in research facilities and a shift toward high-throughput imaging solutions to support the country's expanding pharmaceutical pipeline. China's position as a global pharmaceutical manufacturing hub further strengthens demand for preclinical imaging services.
- The market in China reflects broader trends in Asia Pacific, where emerging economies are investing heavily in research infrastructure to compete in the global life sciences sector..
Key Market Statistics
- CAGR (2024-2029) 5.1% CAGR
- Market Size, 2024 ~USD 32.7 Million
- Forecast, 2029 ~USD 41.9 Million
- Country China
China Preclinical Imaging Market Overview
Market Valuation :
China's preclinical imaging market reached $32.7 million in 2024, with projections to expand to $41.9 million by 2029, representing a robust 5.1% CAGR driven by pharmaceutical innovation.
Government Investment Surge :
Increased government funding in life sciences infrastructure and R&D initiatives is accelerating adoption of advanced preclinical imaging technologies across Chinese research institutions and pharmaceutical companies.
Pharmaceutical R&D Expansion :
China's rapid advancement in drug discovery and development pipelines is creating heightened demand for sophisticated preclinical imaging solutions to support early-stage research and regulatory compliance.
Technology Modernization :
Chinese research facilities are increasingly upgrading to cutting-edge preclinical imaging modalities, including micro-CT, micro-MRI, and optical imaging systems to enhance research capabilities and competitiveness.
China Preclinical Imaging Market Dynamics
- Government initiatives supporting life sciences infrastructure development and increased private sector investment in drug discovery are key catalysts.
- The market benefits from growing collaborations between Chinese research institutions and international pharmaceutical companies, driving technology adoption and modernization across academic and commercial laboratories. The 5.1% CAGR reflects sustained demand for advanced imaging technologies essential for preclinical drug development, safety assessment, and regulatory submissions.
- As China's pharmaceutical industry matures and regulatory standards align with international benchmarks, investment in preclinical imaging capabilities will remain a priority for competitive advantage in the global drug development landscape..
Market Ecosystem
Related Ecosystem
Diagnostic Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- CT Scanners
- Nuclear Imaging
- Positron Emission Tomography
- Siemens healthineers
- PHILIPS HEALTHCARE
- CANON INC.
- FUJIFILM Holdings Corporation
- UNITED IMAGING HEALTHCARE CO., LTD.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- China's preclinical imaging market is valued at $32.7 million in 2024 and will reach $41.9 million by 2029 at a 5.1% CAGR.
- Government investment in life sciences infrastructure and CRO expansion are primary growth drivers for preclinical imaging adoption in China.
- Advanced imaging modalities including micro-CT, micro-MRI, and optical imaging are increasingly integrated into China's drug discovery processes.
- China's role as a global pharmaceutical hub positions the country as a key market for preclinical imaging technology vendors and service providers.
Preclinical Imaging Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | NUCLEAR IMAGING SYSTEMS (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 5% from 2024 to 2029 |
| Largest Segment | PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 4 (2024) |
| Revenue Forecast (Billions) | ~USD 5.1 (2029) |
| Segments Covered | Product, Type, Application, End User |
China Preclinical Imaging Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product
- Imaging Systems
- Reagents
- Software
By Type
- Barium-Based Contrast Agents
- Bioluminescence Imaging Systems
- Fluorescence Imaging Systems
- Gadolinium-Based Contrast Agents
- Gallium-67-Based Spect Probes
- Gastrografin-Based Contrast Agents
- Gold Nanoparticles
- Iodine-131-Based Spect Probes
- Iodine-Based Contrast Agents
- Iron-Based Contrast Agents
- Magnetic Particle Imaging Systems
- Manganese-Based Contrast Agents
- Micro-Ct Systems
- Micro-Mri Systems
- Micro-Ultrasound Systems
- Nuclear Imaging Systems
- Optical Imaging Systems
- Other Optical Imaging Systems
- Other Spect Probes
- Photoacoustic Imaging Systems
- Technetium-99M-Based Spect Probes
- Thallium-201-Based Spect Probes
By Application
- Cardiology
- Immunology & Inflammation
- Infectious Diseases
- Neurology
- Oncology
- Other Applications
By End User
- Academic & Research Centers
- Imaging Centers
- Other End Users
- Pharmaceutical & Biotechnology Companies
CHINA: PRECLINICAL IMAGING MARKET, BY END USER, 2023–2029
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH CENTERS | 50.7 | 53.8 | 57 | 60.5 | 64.2 | 68.1 | 72.2 | 6.1 |
| IMAGING CENTERS | 28.5 | 30.4 | 32.3 | 34.4 | 36.7 | 39 | 41.6 | 6.5 |
| OTHER END USERS | 12.7 | 13.3 | 13.9 | 14.5 | 15.2 | 15.9 | 16.7 | 4.7 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 224.9 | 237.9 | 251.7 | 266.2 | 281.6 | 297.9 | 315.1 | 5.8 |
| TOTAL | 316.7 | 335.3 | 354.9 | 375.7 | 397.7 | 420.9 | 445.5 | 5.8 |
Target Audience
- Pharmaceutical Companies : Chinese and multinational pharma firms need market insights to optimize preclinical imaging investments, accelerate drug development timelines, and ensure compliance with evolving Chinese regulatory requirements.
- Medical Device Manufacturers : Imaging technology providers require China-specific market data to identify growth opportunities, understand institutional buying patterns, and develop localized product strategies for the expanding research sector.
- Research Institutions & Universities : Chinese academic and research centers need market intelligence to justify equipment investments, benchmark against peer institutions, and align imaging capabilities with national research priorities and funding initiatives.
- Investment & Private Equity Firms : Investors evaluating opportunities in China's life sciences sector require detailed market analysis to assess growth potential, identify acquisition targets, and evaluate portfolio companies' market positioning.
- Healthcare Consultants & Analysts : Market research professionals and strategic consultants need China-specific preclinical imaging data to support client advisory work, competitive analysis, and market entry strategies in the pharmaceutical sector.
Key Companies in the China Preclinical Imaging Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| ANALOGIC CORPORATION | United States | Private Company | MRI,PET,SPECT, |
| XILINX, INC. | United States | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| GUERBET GROUP | France | InvalidIdentifier | PET,SPECT,MRI, |
| BRUKER CORPORATION | United States | Public Company | MRI,PET,SPECT, |
| REVVITY, INC. | United States | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| OPTISCAN IMAGING LTD. | Australia | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.
ANALOGIC CORPORATION
Analogic Corporation is a United States-based private company founded in 1967 with 1,510 employees, specializing in medical and aerospace technology solutions.
XILINX, INC.
Xilinx, Inc. is a United States-based private company founded in 1984 with 4,890 employees, operating in the semiconductor and programmable logic industry.
GUERBET GROUP
Guerbet Group is a France-based company in the medical imaging and pharmaceutical sector.
BRUKER CORPORATION
Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees, providing scientific instruments and analytical solutions.
REVVITY, INC.
Revvity, Inc. is a United States-based public company founded in 1937 with 11,000 employees, operating in the life sciences and diagnostics industry.
OPTISCAN IMAGING LTD.
Optiscan Imaging Ltd. is an Australia-based public company founded in 1994 with 9 employees, specializing in optical imaging technology.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise valuation data for China's preclinical imaging market with verified 5.1% CAGR, enabling accurate financial forecasting and investment decision-making for market entry or expansion strategies.
- Government Policy Insights : Understand how Chinese government investments in life sciences infrastructure are reshaping market dynamics, helping stakeholders align product development and sales strategies with policy-driven growth opportunities.
- Competitive Landscape Intelligence : Identify market trends specific to China's pharmaceutical R&D sector, including technology adoption patterns and institutional preferences, to benchmark competitive positioning and identify partnership opportunities.
- Regulatory & Compliance Context : Gain insights into how China's evolving regulatory standards for preclinical imaging are influencing technology requirements and market demand, critical for product localization and compliance strategies.
- Investment & Expansion Planning : Leverage China-specific market data to evaluate market attractiveness, assess growth potential through 2029, and develop targeted go-to-market strategies for pharmaceutical companies and imaging technology providers.
Frequently asked questions
What is the current size of China's preclinical imaging market?
China's preclinical imaging market was valued at $32.7 million in 2024 and is expected to grow to $41.9 million by 2029.
What is the projected growth rate for preclinical imaging in China?
China's preclinical imaging market is projected to grow at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.
What imaging technologies are driving growth in China's preclinical market?
Advanced modalities such as micro-CT, micro-MRI, and optical imaging systems are the primary technologies driving adoption in China's preclinical imaging sector.
Which sectors are the primary end-users of preclinical imaging in China?
Pharmaceutical companies, contract research organizations (CROs), and academic research institutions are the primary end-users of preclinical imaging services in China.
How is China's government supporting preclinical imaging market growth?
China's government is investing in life sciences infrastructure, supporting drug discovery innovation, and modernizing regulatory frameworks to accelerate preclinical imaging adoption.
RESEARCH METHODOLOGY
This market research study utilized extensive secondary sources, directories, and databases to identify and collect information relevant to this technical, market-oriented, and financial analysis of the preclinical imaging market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to gather and verify critical qualitative and quantitative information, as well as to assess market prospects. The size of the preclinical imaging market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was employed to identify and collect information relevant to the comprehensive, technical, market-oriented, and commercial study of the preclinical imaging market. It was also used to obtain important information about key players, market classification, and segmentation according to industry trends, as well as key developments related to market and technology perspectives, down to the most detailed level. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring a basic understanding of the global preclinical imaging market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital personnel, department heads, hospital directors, corporate personnel) and supply side (such as C-level and D-level executives, technology experts, software developers, marketing and sales managers, among others) across five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Breakdown of Primary Interviews
Note: Tiers are defined based on the total revenues of companies. As of 2024, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the global preclinical imaging market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- Key players in the global preclinical imaging market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology included the study of the annual and quarterly financial reports and regulatory filings, data books of major market players, and interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global preclinical imaging market were determined by using secondary sources and verified through primary sources.
- All key macroindicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get validated and verified quantitative and qualitative data.
- The gathered market data was consolidated and added with detailed inputs and analysis and presented in this report.
Global Preclinical Imaging Market: Bottom-up and Top-down Approach
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the preclinical imaging market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the preclinical imaging market.
Market Definition
Preclinical imaging involves the application of molecular imaging for the assessment of anatomical, physiological, and functional parameters in live animal models during preclinical studies. Preclinical imaging systems and reagents are utilized to visualize living animals in order to assess the safety and efficacy of novel drug procedures or other medical treatments for human applications. During preclinical studies, a variety of different imaging modalities are utilized, such as optical imaging systems, nuclear imaging systems (micro-PET and micro-SPECT), micro-MRI, micro-ultrasound systems, and micro-CT imaging systems.
Stakeholders
- Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
- Pharmaceutical and Biotechnology Companies
- Preclinical Imaging Reagent Manufacturers and Suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Market Research and Consulting Service Providers
Report Objectives
- To define, describe, and forecast the preclinical imaging market by product type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
-
To analyze the opportunities in the market for stakeholders and provide details of
the competitive landscape for preclinical imaging market leaders - To profile the key players in the market and comprehensively analyze their market shares and core competencies
-
To forecast the size of the market segments with respect to five main regions:
North America, the Asia Pacific, Europe, Latin America, and the Middle East & Africa - To track and analyze competitive developments, such as partnerships, acquisitions, product launches & approvals, and expansions
- To benchmark players within the preclinical imaging market using the Competitive Evaluation Matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Get the Full Preclinical Imaging Market Report
Full forecast, segment splits, and company analysis for all Preclinical Imaging Market.
- US Preclinical Imaging Market
- Canada Preclinical Imaging Market
- Germany Preclinical Imaging Market
- UK Preclinical Imaging Market
- France Preclinical Imaging Market
- Italy Preclinical Imaging Market
- Spain Preclinical Imaging Market
- Japan Preclinical Imaging Market
- India Preclinical Imaging Market
- Brazil Preclinical Imaging Market
- Mexico Preclinical Imaging Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
